Skip to content

GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors

Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation

Palliative radiation therapy represents 40% of the on-going radiation at the Jewish General Hospital. In a traditional palliative radiation treatment to bulky or radioresistant tumors, radiotherapy schema varies from 24 to 30 Gys given in 3 to 10 fractions, depending on the tumor size, tumor location and tumor pathology. However, for many patients this treatment involves considerable toxicity, travel and time spent at the hospital. Spatially fractionated radiation (SFR) is an alternative technique that consists in delivering one single treatment, given through a grid containing holes. The present study is proposing to validate SFR as a safe and effective mean to palliate patients with symptomatic bulky tumors (more than 8 cm) or with tumors known to be resistant to radiation.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Patient with histologically or cytologically confirmed malignancy. All malignant histologies/cytologies are eligible.
* Patient with bulky tumor (larger than 8cm), or with a tumor known to be resistant to radiation (eg. Melanoma, hypernephroma, sarcoma), or with a tumor previously irradiated with a palliative intent requiring more than 1 fraction of radiation
* Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis
* WHO performance status of 0-2
* Aged 18 years or older
* Ability to sign and understand an informed consent form

Exclusion Criteria:

* Potentially curable patient
* Previous palliative radiation with hypofractionation
* Tumor located near the spinal cord or in the brain
* Pregnant or nursing woman

Study Location

Sir Mortimer Jewish General Hospital
Sir Mortimer Jewish General Hospital
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Harielle Lamarre, BSc

[email protected]
514-340-8222
Study Sponsored By
Sir Mortimer B. Davis - Jewish General Hospital
Participants Required
More Information
Study ID: NCT02333110